Koji Inamori

Koji Inamori

Auto-generated profile, based on publicly available information

Koji Inamori

Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HBHideaki Bando
Hideaki Bando
YTYuichiro Tsukada
Yuichiro Tsukada
KIKoji Inamori
Koji Inamori
YTYosuke Togashi
Yosuke Togashi
SKShohei Koyama
Shohei Koyama
TYTakayuki Yoshino
Takayuki Yoshino
Purpose: Preoperative chemoradiotherapy (CRT) and surgical resection are the standard treatment for locally advanced rectal cancer (LARC). Combining immune checkpoint inhibitors with radiation suggests a promising approach for enhancing efficacy. We investigated the efficacy of CRT followed by nivolumab and surgery in patients with LARC. Patients and Methods: In phase I, we investigated the feasibility of sequentially combined CRT, 5 cycles of nivolumab, and radical surgery. In phase II, patients with microsatellite stable (MSS) and microsatellite instability-high (MSI-H) LARC were evaluated. Results: Three patients in phase I received full courses of CRT and nivolumab without dose modification; the schedule was recommended for phase II. A pathologic complete response (pCR) was centrally confirmed in 30% [11/37; 90% confidence interval (CI), 18%–44%] and 60% (3/5) of the MSS and exploratory MSI-H cohorts, respectively. While immune-related severe adverse events were observed in 3 patients, no treatment-related deaths were observed. In 38 patients with MSS who underwent surgery, pCR rates of 75% (6/8) and 17% (5/30; P = 0.004, Fisher exact test) were observed in those with programmed cell death ligand 1 (PD-L1) tumor proportion score ≥1% and <1%, respectively; IHC staining was performed using pre-CRT samples. In 24 patients with MSS, pre-CRT samples were analyzed by flow cytometry; pCR rates of 78% (7/9) and 13% (2/15; P = 0.003, Fisher exact test) were observed for CD8+ T cell/effector regulatory T cell (CD8/eTreg) ratios of ≥2.5 and <2.5, respectively, in tumor-infiltrating lymphocytes. Conclusions: CRT followed by consolidation nivolumab could increase pCR. PD-L1 expression and an elevated CD8/eTreg ratio were positive predictors in patients with MSS LARC.

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TYTakayuki Yoshino
Takayuki Yoshino
HBHideaki Bando
Hideaki Bando
YTYuichiro Tsukada
Yuichiro Tsukada
KIKoji Inamori
Koji Inamori
SYSatoshi Yuki
Satoshi Yuki
MIMasaaki Ito
Masaaki Ito
3606 Background: Chemoradiotherapy (CRT) with surgery (S) is standard for patients (pts) with locally-advanced rectal cancer (LARC), and nivolumab (nivo) is active in microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). We studied nivo and radical S following CRT (50.4 Gy with capecitabine 1,650 mg/m2) in T3–4 NanyM0 LARC. Methods: Phase I included testing of a recommended phase II dosing schedule (RP2S). Efficacy and safety were studied in phase II pts and those given RP2S in phase I. In Cohort A-1, for microsatellite stable (MSS) LARC pts, the primary endpoint was centrally confirmed pathologic complete response (pCR) rate using AJCC tumor regression grading. The estimated required sample size assuming null and alternative hypotheses pCR = 10% and 30% was 37 pts, with a 1-sided alpha of 5% and power of 90%. Cohort A-2 was exploratory and included a maximum of 5 MSI-H pts. Results: Nivo 240 mg q2 weeks x 5 cycles, following CRT but pre-S, was the RP2S. From 1/17 to 6/18, 37 pts were enrolled in Cohort A-1. Eleven pts (30%; 90% CI 18-44%) showed pCR (AJCC grade (gr) 0). Including the 3 pts (8%) graded AJCC 1, 14 (38%) had major pathologic responses. In addition, clinical CR was observed in 1 pt (3%) refusing S after nivo. Both MSI-H LARC Cohort A-2 pts showed pCRs. Immune-related severe adverse events were observed in 2 pts (gr 3 myasthenia and gr 2 interstitial nephritis); both fully recovered and had S. No treatment-related deaths were observed. pCR rates of 60% (6/10) and 19% (5/27) (p = 0.038, Fisher exact test) were seen in pts with tumor cells with PD-L1 ≥1% and < 1% IHC staining, respectively, performed on biopsy samples taken pre-CRT. Rates of 62% (8/13) and 10% (1/10) (p = 0.029) were seen in 23 pts with samples analyzable by flow cytometry, according to CD8+ lymphocyte /regulatory T cell (CD8/Treg) ratios ≥2 and < 2, respectively. Conclusions: A promising pCR rate of 30%, with mild toxicity, was shown in MSS LARC pts treated with nivo plus radical S. PD-L1 expression and elevated CD8/Treg ratio may be better predictors of nivo benefit, warranting further study in a larger cohort. Clinical trial information: NCT02948348.

1 January 2011 in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
Verified
Journal Article
Open access
KIKoji Inamori
Koji Inamori
AUAkihiro Uno
Akihiro Uno
AFAtsuko Fukazawa
Atsuko Fukazawa
HOHideto Ochiai
Hideto Ochiai
SSShohachi Suzuki
Shohachi Suzuki
HKHiroshi Kitamura
Hiroshi Kitamura

31 March 2023
Verified
Other
Open access
HBHideaki Bando
Hideaki Bando
YTYuichiro Tsukada
Yuichiro Tsukada
KIKoji Inamori
Koji Inamori
YTYosuke Togashi
Yosuke Togashi
SKShohei Koyama
Shohei Koyama
TYTakayuki Yoshino
Takayuki Yoshino
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer

31 March 2023
Verified
Other
Open access
HBHideaki Bando
Hideaki Bando
YTYuichiro Tsukada
Yuichiro Tsukada
KIKoji Inamori
Koji Inamori
YTYosuke Togashi
Yosuke Togashi
SKShohei Koyama
Shohei Koyama
TYTakayuki Yoshino
Takayuki Yoshino
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer

31 March 2023
Verified
Other
Open access
HBHideaki Bando
Hideaki Bando
YTYuichiro Tsukada
Yuichiro Tsukada
KIKoji Inamori
Koji Inamori
YTYosuke Togashi
Yosuke Togashi
SKShohei Koyama
Shohei Koyama
TYTakayuki Yoshino
Takayuki Yoshino
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer